SANOFI-EFC11785



Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
Cabazitaxel
EFC11785
NCT01308580
Prostatic Neoplasm, Prostate Cancer
Phase 3
 
Datasets and document are available as per Sanofi Policy and criteria
August 2017